Cleveland BioLabs Receives Letter From NASDAQ Citing Non-Compliance With Global Market Listing Requirements
Cleveland BioLabs Receives Letter From NASDAQ Citing Non-Compliance With Global Market Listing Requirements
CBLI ) today announced that on October 22, 2008, the Company received a letter from The NASDAQ Stock Market notifying the Company that it had ceased to remain in compliance with Marketplace Rule 44…
Add A Comment